178 related articles for article (PubMed ID: 31539715)
1. Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia.
Wyld D; Wan MH; Moore J; Dunn N; Youl P
Cancer Epidemiol; 2019 Dec; 63():101598. PubMed ID: 31539715
[TBL] [Abstract][Full Text] [Related]
2. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
3. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
4. Incidence, survival and stage at diagnosis of small intestinal neuroendocrine tumours in Queensland, Australia, 2001-2015.
Wyld D; Moore J; Tran N; Youl P
Asia Pac J Clin Oncol; 2021 Aug; 17(4):350-358. PubMed ID: 33567164
[TBL] [Abstract][Full Text] [Related]
5. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
[TBL] [Abstract][Full Text] [Related]
6. Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993-2010.
Youlden DR; Soyer HP; Youl PH; Fritschi L; Baade PD
JAMA Dermatol; 2014 Aug; 150(8):864-72. PubMed ID: 24943712
[TBL] [Abstract][Full Text] [Related]
7. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006.
Navalkele P; O'Dorisio MS; O'Dorisio TM; Zamba GK; Lynch CF
Pediatr Blood Cancer; 2011 Jan; 56(1):50-7. PubMed ID: 21108439
[TBL] [Abstract][Full Text] [Related]
8. Malignant neuroendocrine tumors: incidence and outcomes in pediatric patients.
Allan B; Davis J; Perez E; Lew J; Sola J
Eur J Pediatr Surg; 2013 Oct; 23(5):394-9. PubMed ID: 23444065
[TBL] [Abstract][Full Text] [Related]
9. Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry.
Caldarella A; Crocetti E; Paci E
Pathol Oncol Res; 2011 Sep; 17(3):759-63. PubMed ID: 21476126
[TBL] [Abstract][Full Text] [Related]
10. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project.
van der Zwan JM; Trama A; Otter R; Larrañaga N; Tavilla A; Marcos-Gragera R; Dei Tos AP; Baudin E; Poston G; Links T;
Eur J Cancer; 2013 Jul; 49(11):2565-78. PubMed ID: 23541566
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
12. An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan.
Chang JS; Chen LT; Shan YS; Chu PY; Tsai CR; Tsai HJ
Sci Rep; 2021 Apr; 11(1):7881. PubMed ID: 33846396
[TBL] [Abstract][Full Text] [Related]
13. Change in incidence, characteristics and management of colorectal neuroendocrine tumours in the Netherlands in the last decade.
Kooyker AI; Verbeek WH; van den Berg JG; Tesselaar ME; van Leerdam ME
United European Gastroenterol J; 2020 Feb; 8(1):59-67. PubMed ID: 32213058
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province, 1994-2004.
Alsina M; Marcos-Gragera R; Capdevila J; Buxó M; Ortiz RM; Barretina P; Vilardell L; Brunet J; Beltran M; Izquierdo Á
Cancer Epidemiol; 2011 Dec; 35(6):e49-54. PubMed ID: 21840785
[TBL] [Abstract][Full Text] [Related]
15. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
[TBL] [Abstract][Full Text] [Related]
16. Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources.
Darbà J; Marsà A
BMC Cancer; 2019 Dec; 19(1):1226. PubMed ID: 31842791
[TBL] [Abstract][Full Text] [Related]
17. Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study.
Gudmundsdottir H; Möller PH; Jonasson JG; Björnsson ES
Scand J Gastroenterol; 2019 Jan; 54(1):69-75. PubMed ID: 30638086
[TBL] [Abstract][Full Text] [Related]
18. Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival.
Yang Z; Wang W; Lu J; Pan G; Pan Z; Chen Q; Liu W; Zhao Y
Cell Physiol Biochem; 2018; 45(1):389-396. PubMed ID: 29402806
[TBL] [Abstract][Full Text] [Related]
19. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971.
Ellis L; Shale MJ; Coleman MP
Am J Gastroenterol; 2010 Dec; 105(12):2563-9. PubMed ID: 20823835
[TBL] [Abstract][Full Text] [Related]
20. Non-functional pancreatic neuroendocrine tumours: emerging trends in incidence and mortality.
Wu J; Sun C; Li E; Wang J; He X; Yuan R; Yi C; Liao W; Wu L
BMC Cancer; 2019 Apr; 19(1):334. PubMed ID: 30961556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
